BioSpace News Archive

According to The Insight Partners market research study titled “3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019.

Arthrosi Therapeutics, Inc. announced results from its Phase 2a study investigating the efficacy and safety of its potent urate lowering agent AR882

The report highlights trends prevailing in the global biofilms treatment market, and the factors driving and restraining the market growth.

According to our latest study on “Artificial Tears Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Delivery Mode, and Application,” the market was valued at US$ 2,612.91 million in 2020 and is projected to reach US$ 3,961.63 million by 2028; it is expected to grow at a CAGR of 5.5% from 2021 to 2028.

The report highlights the key factors driving the market growth and prominent players with their developments in the market.

On the other hand, strict government guidelines and lack of knowledge about detailed examination are likely to have a negative impact on the growth of the market in the coming years.

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the results from the Phase 3 long-term safety and efficacy study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd.

Quipt Home Medical Corp., a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced its second quarter fiscal 2021 financial results and operational highlights.

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that a peer-reviewed article on the ongoing NIPU Phase II trial of the Company’s universal cancer vaccine, UV1, in malignant pleural mesothelioma (MPM) has been published

Telix Pharmaceuticals Limited announces that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.